HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, has completed a pilot study assessing the effect of its HempFusion formulation CBD Capsules(R) (HempFusion 20mg CBD capsules with botanical terpenes) as it relates to a combination of anti-inflammatories in lowering the results of the chronic inflammation test. The study was conducted in collaboration with Kansas-based Inflammatory Markers Laboratory (“IML”). In addition, the company also released a white paper titled, “Oral Formulation May Modulate Thromboxane Production.” The white paper was s co-authored by IML director Gordon Ens and George Fritsma, a professor at University of Alabama; the paper focuses on the potential of tracking and elucidating biomarkers sensitive to inflammation in addition to how novel compounds and formulas modulate the expression of these markers. Pilot study results showed potential promise in the area of inflammatory markers and possible effects on exaggerated inflammation. “We are committed to furthering research in the area of hemp-derived CBD,” said HempFusion co-founder and CEO Jason Mitchell in the press release. “And this pilot trial and soon to be published white paper reinforces our continued focus on the safe and effective use of hemp-derived CBD products.”
To view the full press release, visit https://ibn.fm/4y7j2
About HempFusion Wellness Inc.
HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research and HF Labs, to approximately 4,000 retailers across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 46 SKUs (“SKUs”) including tinctures, proprietary FDA Drug Listed over-the-counter (“OTC”) topicals, doctor/practitioner lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex(TM) and are available in store or online. For more information about the company, visit www.HempFusion.com.
NOTE TO INVESTORS: The latest news and updates relating to CBDHF are available in the company’s newsroom at https://ibn.fm/CBDHF
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
